Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas

Launched by UNIVERSITY HOSPITAL REGENSBURG · Mar 14, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on studying how well different treatments work for certain brain tumors, specifically in adolescents and young adults aged 15 to 39. These tumors include types known as gliomas, medulloblastomas, and ependymomas, which can be quite serious and challenging to treat. The researchers want to create a better system for understanding these tumors by using various tools like MRI scans, tumor samples, and other clinical information. The goal is to improve the way these tumors are diagnosed and treated, ultimately leading to better outcomes for patients.

To be eligible for this trial, participants must be newly diagnosed with a high-risk brain tumor, have a good level of health (meaning they can do daily activities), and be expected to live for at least six months after joining the study. They will also need to give consent, or have their legal guardian give consent, before starting. Participants can expect to undergo different assessments and treatments as part of the study, contributing to important research that could help others with similar conditions in the future. It's important to note that the trial is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. first diagnosis of high-risk CNS tumors including glioma IDHmutated, medulloblastoma, ependymoma and other intra-axial primary brain tumors
• • 2. adolescents and young adults (AYA; 15 to 39 years)
• • 3. Karnofsky status of 60 or higher
• • 4. resection, extended biopsy or stereotactic biopsy with sufficient tissue volume
• • 5. multimodal therapy planned at the discretion of the treating specialist
• • 6. expected survival time of at least 6 months
• • 7. informed consent from the patient or the patient's legal guardian prior to the first study procedure
• • 8. complete material collection expected.
• Exclusion Criteria:
• • 1. synchronous independent tumor disease other than basal cell carcinoma and carcinoma in situ
• • 2. participation in interventional clinical trial except in standard arms of interventional clinical trials.